AR014975A1 - CALCILITICAL COMPOUNDS, A PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS THEM, AND THE USE OF THEM FOR THE MANUFACTURE OF A MEDICINAL PRODUCT - Google Patents

CALCILITICAL COMPOUNDS, A PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS THEM, AND THE USE OF THEM FOR THE MANUFACTURE OF A MEDICINAL PRODUCT

Info

Publication number
AR014975A1
AR014975A1 ARP990101555A ARP990101555A AR014975A1 AR 014975 A1 AR014975 A1 AR 014975A1 AR P990101555 A ARP990101555 A AR P990101555A AR P990101555 A ARP990101555 A AR P990101555A AR 014975 A1 AR014975 A1 AR 014975A1
Authority
AR
Argentina
Prior art keywords
alkyl
group
alkylene
substituted
riv
Prior art date
Application number
ARP990101555A
Other languages
Spanish (es)
Original Assignee
Nps Pharma Inc
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nps Pharma Inc, Smithkline Beecham Corp filed Critical Nps Pharma Inc
Publication of AR014975A1 publication Critical patent/AR014975A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/54—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un compuesto calcilítico que comprende la formula (I), en la que: Y1 es un enlace covalente, alquileno o alquenileno de hasta 4 átomos de carbono, sinsustituir o sustituido con alquilo de C1-4 u O; Y2 es metileno, sin sustituir o sustituido con alquilo haloalquilo de C1-4; Y3 es un enlace covalenteu O, S, N-RIV o alquileno de C1-4-O, alquileno de C1-4-S, o alquileno de C1-4-N-RIV; RIV se selecciona entre el grupo que consta de H, alquilo de C1-4, ocicloalquilo de C3-6; R3 y R4 son, independientemente, metilo o etilo, o, juntos, forman ciclopropilo; R5 es heteroarilo o heteroarilo fusionado; en elque el anillo heterocíclico contiene N, O o S, y es aromático, dihidro o tetrahidro, sin sustituir o sustituido con cualesquiera sustituyentes seleccionadosentre el grupo que consta de OH, OCH3, (CH3)2, halogeno, alquilo de C1-4, alcoxi de C1-4, cicloalquilo de C3-6, OSO2RIV, CN,NO2, OCF3, CF3, CH2CF3, (CH2)nCO2H,(CH2)nCO2RIV; n es un numero entero de 0 a 3; G es un enlace covalente, CHR6 o C-R6, en cuyas formulas R6 es H, OH u O (formando una cetona); R7 es H, OH,u O-alquilo de C1-4; R8 es H o alquilo de C1-4;o R7 y R8 juntos forman una cetona; A y B se seleccionan independientemente entre el grupo que consta de unenlace, CH2, NH, O, S yC=O, con tal que o bien A o B se seleccione entre CH2 y NH; o A y B juntos forman un enlace; o el resto A-B está representado porCH=CH o C:::C; X se selecciona entre las subformulas (Ia) a (Ie); en las que: W se selecciona entre el grupo que consta de R1, SO2R1, C(O)R1, SO2NR1R1,C(O)NR1R1, C(O)OR1, y SO3R1, en cuyas formulas R1 y R1 se seleccionan independientemente entre el grupo que consta de hidrogeno, alquilo de C1-4,cicloalquilo de C3-6, alquenilo de C2-5, alquinilo de C2-5, heterocicloalquilo, arilo y aril-alquilo de C1-4; o R1 y R1 juntos forman un anillo heterocíclicode 3 a 7 miembros opcionalmente sustituido; en el que cualesquiera sustituyentes se seleccionan entre el grupo que consta de CN, arilo, CO2R, CO2NHR, OH, OR,NH2, halo,CF3, OCF3 y NO2; en cuyas formulas R representa alquilo de C1-4 o cicloalquilo de C3-6; X1 se selecciona entre el grupo que consta de CN, NO2, ClA calcilytic compound comprising formula (I), in which: Y1 is a covalent, alkylene or alkenylene bond of up to 4 carbon atoms, unsubstituted or substituted with C1-4 or O alkyl; Y2 is methylene, unsubstituted or substituted with C1-4 haloalkyl alkyl; Y3 is a covalent bond O, S, N-RIV or C1-4-O alkylene, C1-4-S alkylene, or C1-4-N-RIV alkylene; RIV is selected from the group consisting of H, C 1-4 alkyl, C 3-6 alkylcycloalkyl; R3 and R4 are, independently, methyl or ethyl, or, together, form cyclopropyl; R5 is fused heteroaryl or heteroaryl; wherein the heterocyclic ring contains N, O or S, and is aromatic, dihydro or tetrahydro, unsubstituted or substituted with any substituents selected from the group consisting of OH, OCH3, (CH3) 2, halogen, C1-4 alkyl, C1-4 alkoxy, C3-6 cycloalkyl, OSO2RIV, CN, NO2, OCF3, CF3, CH2CF3, (CH2) nCO2H, (CH2) nCO2RIV; n is an integer from 0 to 3; G is a covalent bond, CHR6 or C-R6, in which formulas R6 is H, OH or O (forming a ketone); R7 is H, OH, or C1-4 O-alkyl; R8 is H or C1-4 alkyl; or R7 and R8 together form a ketone; A and B are independently selected from the group consisting of a link, CH2, NH, O, S and C = O, provided that either A or B is selected from CH2 and NH; or A and B together form a bond; or the remainder A-B is represented by CH = CH or C ::: C; X is selected from the subforms (Ia) to (Ie); in which: W is selected from the group consisting of R1, SO2R1, C (O) R1, SO2NR1R1, C (O) NR1R1, C (O) OR1, and SO3R1, in which formulas R1 and R1 are independently selected from the group consisting of hydrogen, C1-4 alkyl, C3-6 cycloalkyl, C2-5 alkenyl, C2-5 alkynyl, heterocycloalkyl, aryl and aryl C1-4 alkyl; or R1 and R1 together form an optionally substituted 3 to 7 member heterocyclic ring; wherein any substituents are selected from the group consisting of CN, aryl, CO2R, CO2NHR, OH, OR, NH2, halo, CF3, OCF3 and NO2; in whose formulas R represents C1-4 alkyl or C3-6 cycloalkyl; X1 is selected from the group consisting of CN, NO2, Cl

ARP990101555A 1998-04-08 1999-04-06 CALCILITICAL COMPOUNDS, A PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS THEM, AND THE USE OF THEM FOR THE MANUFACTURE OF A MEDICINAL PRODUCT AR014975A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8108798P 1998-04-08 1998-04-08

Publications (1)

Publication Number Publication Date
AR014975A1 true AR014975A1 (en) 2001-04-11

Family

ID=22162024

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990101555A AR014975A1 (en) 1998-04-08 1999-04-06 CALCILITICAL COMPOUNDS, A PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS THEM, AND THE USE OF THEM FOR THE MANUFACTURE OF A MEDICINAL PRODUCT

Country Status (7)

Country Link
EP (1) EP1069901A4 (en)
JP (1) JP2002510636A (en)
AR (1) AR014975A1 (en)
AU (1) AU3551399A (en)
CA (1) CA2327188A1 (en)
CO (1) CO5021223A1 (en)
WO (1) WO1999051241A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO5180628A1 (en) * 1999-07-31 2002-07-30 Smithkline Beecham Corp CALCIOLITIC COMPOUNDS
MY159417A (en) * 2000-01-24 2017-01-13 Smithkline Beecham Corp Calcilytic compounds
US20030018203A1 (en) 2002-07-17 2003-01-23 Largo Maria Amparo Calcilytic compounds
WO2002007673A2 (en) * 2000-07-21 2002-01-31 Smithkline Beecham Corporation Calcilytic compounds
FR2812875B1 (en) 2000-08-08 2003-12-12 Centre Nat Rech Scient NOVEL DIAMINES HAVING CASR MODULATING ACTIVITY AND THEIR METHOD OF PREPARATION
AU2001277752A1 (en) * 2000-08-11 2002-02-25 Japan Tobacco Inc. Calcium receptor antagonists
ATE343390T1 (en) * 2000-10-25 2006-11-15 Smithkline Beecham Corp CALCILYTIC COMPOUNDS
US6476046B1 (en) 2000-12-04 2002-11-05 Sepracor, Inc. Diazabicyclo[4.3.0]nonanes, and methods of use thereof
AU2003247425B2 (en) 2002-05-22 2007-03-08 Amgen Inc. Amino-pyridine, -pyridine and pyridazine derivatives for use as vanilloid receptor ligands for the treatment of pain
BR0313255A (en) 2002-08-08 2005-07-12 Amgen Inc Compound, pharmaceutical composition, use of a compound and methods of making a medicament and preparing a compound
AR042132A1 (en) 2002-11-26 2005-06-08 Smithkline Beecham Corp COMPOUND OF 2- HYDROXI -3- (2- ARIL - 1, 1 - DIMETHYLETHYLAMINE) PROPOXIFENILO, PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS AND USES IT TO PREPARE IT
US7105537B2 (en) 2003-01-28 2006-09-12 Bristol-Myers Squibb Company 2-substituted cyclic amines as calcium sensing receptor modulators
US7205322B2 (en) 2003-02-12 2007-04-17 Bristol-Myers Squibb Company Thiazolidine compounds as calcium sensing receptor modulators
DK1619180T3 (en) 2003-04-23 2010-03-29 Japan Tobacco Inc CASR antagonist
US7265145B2 (en) 2003-05-28 2007-09-04 Bristol-Myers Squibb Company Substituted piperidines and pyrrolidines as calcium sensing receptor modulators and method
JPWO2004106280A1 (en) 2003-05-28 2006-07-20 日本たばこ産業株式会社 CaSR antagonist
WO2005077938A1 (en) 2004-02-11 2005-08-25 Amgen Inc. Vanilloid receptor ligands and their use in treatments
MY139645A (en) 2004-02-11 2009-10-30 Amgen Inc Vanilloid receptor ligands and their use in treatments
US7301022B2 (en) 2005-02-15 2007-11-27 Amgen Inc. Vanilloid receptor ligands and their use in treatments
WO2010103429A1 (en) 2009-03-10 2010-09-16 Pfizer Inc. 1,1-(Dimethyl-Ethylamino)-2-Hydroxy-Propoxy]-Ethyl}-3-Methyl-Biphenyl-4- Carboxylic Acid Derivatives As Calcium Receptor Antagonists

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL83966A (en) * 1986-09-26 1992-03-29 Schering Ag Amides of aminopolycarboxylic acids and pharmaceutical compositions containing them
UY24949A1 (en) * 1997-04-08 2001-04-30 Smithkline Beecham Corp CALCILITE COMPOUNDS

Also Published As

Publication number Publication date
EP1069901A1 (en) 2001-01-24
WO1999051241A1 (en) 1999-10-14
JP2002510636A (en) 2002-04-09
AU3551399A (en) 1999-10-25
CO5021223A1 (en) 2001-03-27
EP1069901A4 (en) 2001-06-13
CA2327188A1 (en) 1999-10-14

Similar Documents

Publication Publication Date Title
AR014975A1 (en) CALCILITICAL COMPOUNDS, A PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS THEM, AND THE USE OF THEM FOR THE MANUFACTURE OF A MEDICINAL PRODUCT
AR016510A1 (en) ARYLCYLCAMINIC CALCILITICAL DERIVATIVES, A PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM AND THE USE OF SUCH DERIVATIVES FOR THE MANUFACTURE OF A MEDICINE
AR018177A1 (en) CALCILITICAL COMPOUNDS, A PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS THEM AND THE USE OF THEM FOR THE MANUFACTURE OF A MEDICINAL PRODUCT.
HUP0402313A2 (en) Phenyl-piperazine derivatives as serotonin reuptake inhibitors, pharmaceutical compositions containing them and use thereof
HUP0401982A2 (en) Indolizine derivates, process for their preparation and pharmaceutical compositions containing the compounds
PT1289955E (en) PIPERIDINES FOR USE AS ANTAGONISTS OF OREXINE RECEPTORS
DK1260512T3 (en) Hitherto unknown cyclic amide derivatives
ECSP067013A (en) 2-QUINOLIL-OXAZOLES REPLACED USEFUL AS PDE INHIBITORS4
AR038240A1 (en) PIPERIDINE COMPOUND, USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND PROCEDURE FOR PREPARATION
EA200200942A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING DERIVATIVES 3-AMINOAZETIDINE, NEW DERIVATIVES AND METHOD FOR THEIR PREPARATION
UA72917C2 (en) Cyclic carbamates derivatives, pharmaceutical composition containing said derivatives of cyclic carbamates and active ingredients as modulators of the progesterone receptor
HUP0300641A2 (en) Triazaspiro[5.5]undecane derivatives and pharmaceutical compositions containing the same as the active ingredient
TW200716100A (en) Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents
HUP0302918A2 (en) Antimicrobial oxazolidinone derivatives, and pharmaceutical compositions containing the same and process for preparation of compounds
ECSP045369A (en) DERIVATIVES OF N- [PHENYL (PIPERIDIN-2-IL) METIL] BENZAMIDA, ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS
HRP20050390A2 (en) Substituted benzoxazinones and uses thereof
HUP0300052A2 (en) Piperidine and piperazine derivatives which function as 5-ht2a receptor antagonists, process for their preparation and pharmaceutical compositions containing them
HUP0003748A2 (en) Halogen substituted tetracyclic tetrahydrofuran derivatives, process for their preparation and pharmaceutical compositions containing the same
AR038404A1 (en) USEFUL NICOTINAMIDE DERIVATIVES AS PDE4 INHIBITORS, PROCEDURE FOR THE PREPARATION OF THE COMPOUND AND PHARMACEUTICAL COMPOSITION THAT INCLUDES IT
AR034174A1 (en) BENZOXAZINONE COMPOUNDS, PROCEDURE FOR THE PREPARATION, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE IT, PROCEDURE FOR THE PREPARATION OF SUCH COMPOSITIONS, AND THE USE OF SUCH COMPOUNDS OR COMPOSITIONS IN THE MANUFACTURE OF MEDICINES
CO5650231A2 (en) DERIVATIVES OF 1- (ALQUILAMINOALQUIL-PIRROLIDIN- / PIPERIDINIL) -2,2-DIFENYLACETAMIDE AS ANTAGONISTS OF THE MUSCARINIC RECEIVER, ITS SYNTHESIS PROCEDURE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
HUP0402261A2 (en) Piperidine derivatives and their use as modulators of chemokine receptor activity, process for their preparation and pharmaceutical compositions containing them
AR007108A1 (en) ANTI-TUMOR AND ANTIVIRAL RENTAL AGENTS, PROCEDURE FOR THEIR PREPARATION, USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT AND PHARMACEUTICAL COMPOSITION CONTAINING SUCH AGENTS.
ATE276257T1 (en) PYRAZINONE DERIVATIVES
EA200300044A1 (en) NEW SUBSTITUTED PHTHALIDES, METHOD OF THEIR PRODUCTION AND CONTAINING THEIR PHARMACEUTICAL COMPOSITIONS

Legal Events

Date Code Title Description
FA Abandonment or withdrawal